Alembic Pharma receives USFDA approval for Solifenacin Succinate

Alembic Pharmaceuticals has received USFDA approval for Solifenacin Succinate tablets which are used for treatment of over-active bladder. The product Solifenacin Succinate is a generic equivalent of Vesicare tablets of Astellas Pharma US Inc.

According to market estimates, Solifenacin Succinate tablets 5 mg and 10 mg had an estimated market size of USD 967 million for 12 months, ending December 2018.

Company Profile : Alembic Pharmaceuticals Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.